A new study has revealed a sharp rise in attention deficit hyperactivity disorder cases in Finland, with both incidence and prevalence more than doubling between 2015 and 2020. The findings, published in the journal Brain and Behaviour, highlight notable differences in diagnosis rates by age and gender, leading to discussions about evolving diagnostic practices and awareness.
The nationwide register-based study found that ADHD prevalence was consistently higher in males, particularly among children and adolescents. In 2020, the prevalence of ADHD among boys aged 6 to 12 was 5.1 percent, increasing to 8 percent in those aged 13 to 17. For girls, the prevalence in these age groups was significantly lower at 2.3 percent. Despite this gender gap, the study noted that the relative increase in ADHD diagnoses was more pronounced in females, suggesting that growing awareness may be leading to more diagnoses among girls and women.
The research also examined ADHD medication use, revealing that the proportion of diagnosed patients receiving medication remained stable at around 80 percent over the study period. Methylphenidate was the most commonly prescribed medication, aligning with national treatment guidelines that favour its use as a first-line treatment. While overall medication use was higher in males, an unexpected pattern emerged in adulthood. The proportion of women receiving ADHD medication surpassed that of men in the 18 to 24 and 55 to 64 age groups, indicating a shift in how the condition is managed across different stages of life.
A particularly striking trend in the study was the drop in ADHD medication use during the transition from adolescence to adulthood. This decline was most evident in males, raising questions about potential barriers to continued treatment. Researchers suggested that changes in healthcare provision might play a role, as young adults must transition from adolescent psychiatric services to adult mental health services, which may cause disruptions in care. Another factor influencing medication use could be Finland’s military service requirements, which discourage the use of ADHD medication among recruits, potentially leading some young men to discontinue treatment.
Regional differences were also observed, with higher ADHD prevalence rates recorded in the northern parts of Finland. The reasons for these disparities remain unclear, though they may be linked to variations in healthcare access, diagnostic practices, or environmental factors. Similar trends have been noted in other Nordic countries, suggesting that the rise in ADHD diagnoses is part of a broader regional pattern rather than a phenomenon unique to Finland.
The study’s findings contribute to ongoing debates about whether the rising prevalence of ADHD reflects genuine increases in the condition or improved recognition and diagnosis. Researchers acknowledged that greater awareness and refined diagnostic criteria could explain much of the increase. But oncerns persist about potential overdiagnosis or misdiagnosis, particularly as ADHD symptoms overlap with other conditions such as anxiety and mood disorders.
